ArticleCancers2019
KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma.Cell reports · 2025Article
- Mendelian randomization analyses support causal relationships between unswitched memory B cells and lung squamous cell carcinoma.Discover oncology · 2025Article
- [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Identification of PANoptosis Subtypes to Assess the Prognosis and Immune Microenvironment of Lung Adenocarcinoma Patients: A Bioinformatics Combined Machine Learning Study.Current cancer drug targets · 2025Article
- Unveiling the role ofTranslational cancer research · 2024Article
- [miR-2110 Affects the Biological Behaviors of Lung Adenocarcinoma by Regulating CDT1].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.BMC medical genomics · 2023Article
- Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma.Aging · 2023Article
- High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.Cancer cell · 2022Article
- The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis.Cancers · 2022Review
- Article
- Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.Annals of translational medicine · 2022Article
- Molecular Characteristics and the Effect ofOncoTargets and therapy · 2022Article
- Identification and Validation of a GPX4-Related Immune Prognostic Signature for Lung Adenocarcinoma.Journal of oncology · 2022Article
- B cell deficiency promotes the initiation and progression of lung cancer.Frontiers in oncology · 2022Article
- Article
- Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.Virchows Archiv : an international journal of pathology · 2021Article
- [CCL18 Promotes the Invasion of Lung Adenocarcinoma through ANXA2].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- CREB stimulates GPX4 transcription to inhibit ferroptosis in lung adenocarcinoma.Oncology reports · 2021Article
- Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisingly, we found that our cohort has a very low mutational burden if we consider our panel as its surrogate. Regarding gene expression data, we identified 31 genes significantly deregulated in tumor tissues compared with a pool of normal samples. Unsupervised hierarchical clustering of the deregulated genes is able to identify two clusters of tumor samples, differently enriched in alterations in actionable genes. In particular, we identified a cluster enriched in patients carrying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.